![Novartis' Cosentyx Moves Closer to a 4th Indication with Positive Data in Spondyloarthritis Trial – Intelligence Pharma Novartis' Cosentyx Moves Closer to a 4th Indication with Positive Data in Spondyloarthritis Trial – Intelligence Pharma](https://intelligencepharma.files.wordpress.com/2019/09/psa-sensoready-pens.jpg)
Novartis' Cosentyx Moves Closer to a 4th Indication with Positive Data in Spondyloarthritis Trial – Intelligence Pharma
INSTRUCTIONS FOR USE COSENTYX® [koe-sen-tix] (secukinumab) injection, for subcutaneous use 300 mg/2 mL single-dose prefilled sy
INSTRUCTIONS FOR USE COSENTYX® [koe-sen-tix] (secukinumab) injection, for subcutaneous use 300 mg/2 mL single-dose prefilled sy
![Efficacy, safety and usability of secukinumab administration by autoinjector/pen in psoriasis: a randomized, controlled trial (JUNCTURE) - Paul - 2015 - Journal of the European Academy of Dermatology and Venereology - Wiley Online Library Efficacy, safety and usability of secukinumab administration by autoinjector/pen in psoriasis: a randomized, controlled trial (JUNCTURE) - Paul - 2015 - Journal of the European Academy of Dermatology and Venereology - Wiley Online Library](https://onlinelibrary.wiley.com/cms/asset/9d436a81-d233-4012-a39b-c95538c59a1f/jdv12751-fig-0002-m.jpg)